EBR Systems, Inc.

EBR Systems, Inc. is a biotechnology company founded in 2003 and headquartered in the United States. The company is focused on revolutionizing treatment for cardiac rhythm diseases through the development of wireless cardiac stimulation technologies. Their flagship product, the WiSE® CRT System, aims to address the limitations of traditional Cardiac Resynchronization Therapy (CRT) by eliminating the need for a lead to the heart’s left ventricle, thus reducing associated complications. EBR Systems, Inc.'s commitment is reflected in its recent $30.00M Private Equity Round investment, which was secured on 27 August 2019. The investment was contributed by notable firms including Ascension Ventures, Emergent Medical Partners, Split Rock Partners, M. H. Carnegie, and Brandon Capital. It's important to note that the WiSE® CRT System is currently an investigational device, limited by US Law to investigational use only.